Global Search

Hide Filters

Showing 1489 results

Press release / Sep 28, 2016

Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine

ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo…
Press release / Nov 08, 2017

Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer

MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal…
Press release / Nov 06, 2017

Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years

For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx® have no radiographic progression of the spine at 4 years[1] These new data…
Press release / Jun 11, 2015

Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and soles

Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients…
Press release / May 15, 2016

Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations

FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
Press release / Mar 20, 2015

New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients

CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
Press release / Apr 16, 2018

Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

Heart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE…
Press release / Jun 23, 2017

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63…
Press release / Feb 16, 2018

Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis

Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/…
Press release / Oct 10, 2015

Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years

Late-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had…